Caseware UK (AP4) 2023.0.135 2023.0.135 2024-07-312024-07-31The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.true2023-08-0112false11truefalse 05070316 2023-08-01 2024-07-31 05070316 2022-08-01 2023-07-31 05070316 2024-07-31 05070316 2023-07-31 05070316 c:Director1 2023-08-01 2024-07-31 05070316 d:PlantMachinery 2023-08-01 2024-07-31 05070316 d:PlantMachinery 2024-07-31 05070316 d:PlantMachinery 2023-07-31 05070316 d:PlantMachinery d:OwnedOrFreeholdAssets 2023-08-01 2024-07-31 05070316 d:MotorVehicles 2023-08-01 2024-07-31 05070316 d:MotorVehicles 2024-07-31 05070316 d:MotorVehicles 2023-07-31 05070316 d:MotorVehicles d:OwnedOrFreeholdAssets 2023-08-01 2024-07-31 05070316 d:FurnitureFittings 2023-08-01 2024-07-31 05070316 d:OwnedOrFreeholdAssets 2023-08-01 2024-07-31 05070316 d:Goodwill 2023-08-01 2024-07-31 05070316 d:Goodwill 2024-07-31 05070316 d:Goodwill 2023-07-31 05070316 c:FRS102 2023-08-01 2024-07-31 05070316 c:AuditExempt-NoAccountantsReport 2023-08-01 2024-07-31 05070316 c:FullAccounts 2023-08-01 2024-07-31 05070316 c:PrivateLimitedCompanyLtd 2023-08-01 2024-07-31 05070316 e:PoundSterling 2023-08-01 2024-07-31 iso4217:GBP xbrli:pure

Registered number: 05070316










E J'S PHARMACEUTICALS LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 JULY 2024

 
E J'S PHARMACEUTICALS LIMITED
REGISTERED NUMBER: 05070316

STATEMENT OF FINANCIAL POSITION
AS AT 31 JULY 2024

2024
2023
Note
£
£

  

Fixed assets
  

Tangible assets
 5 
20,624
13,859

  
20,624
13,859

Current assets
  

Stocks
  
64,747
61,664

Debtors
  
425,059
402,993

Cash at bank and in hand
  
515,280
504,235

  
1,005,086
968,892

Creditors: amounts falling due within one year
  
(321,961)
(282,407)

Net current assets
  
 
 
683,125
 
 
686,485

Total assets less current liabilities
  
703,749
700,344

  

Provisions for liabilities
  

Deferred taxation
  
(4,700)
(3,457)

  
 
 
(4,700)
 
 
(3,457)

  

Net assets excluding pension asset
  
699,049
696,887

Net assets
  
699,049
696,887


Capital and reserves
  

Called up share capital 
  
200
200

Profit and loss account
  
698,849
696,687

  
699,049
696,887


Page 1

 
E J'S PHARMACEUTICALS LIMITED
REGISTERED NUMBER: 05070316
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 JULY 2024

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the income statement in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 



Mr H Jetha
Director

Date: 14 April 2025

The notes on pages 3 to 8 form part of these financial statements.

Page 2

 
E J'S PHARMACEUTICALS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2024

1.


General information

E J's Pharmaceuticals Limited is a private company limited by share capital, incorporated in England and Wales under registration number 05070316. The address of the registered office is Level 5A, Maple House, 149 Tottenham Court Road, London, W1T 7NF.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

Page 3

 
E J'S PHARMACEUTICALS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2024

2.Accounting policies (continued)

 
2.3

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

 
2.4

Government grants

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.
Grants of a revenue nature are recognised in the Income Statement in the same period as the related expenditure.

 
2.5

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the Company in independently administered funds.

Page 4

 
E J'S PHARMACEUTICALS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2024

2.Accounting policies (continued)

 
2.6

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.


 
2.7

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 Amortisation is provided on the following bases:

Goodwill
-
10%
straight line

 
2.8

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 5

 
E J'S PHARMACEUTICALS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2024

2.Accounting policies (continued)


2.8
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Delivery van
-
25%
reducing balance
Fixtures & fittings
-
15%
reducing balance

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.9

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.10

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.11

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.12

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The average monthly number of employees, including directors, during the year was 11 (2023 - 12).

Page 6

 
E J'S PHARMACEUTICALS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2024

4.


Intangible assets



Goodwill

£



Cost


At 1 August 2023
912,000



At 31 July 2024

912,000



Amortisation


At 1 August 2023
912,000



At 31 July 2024

912,000



Net book value



At 31 July 2024
-



At 31 July 2023
-



Page 7

 
E J'S PHARMACEUTICALS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2024

5.


Tangible fixed assets





Fixtures & fittings
Delivery van
Total

£
£
£



Cost or valuation


At 1 August 2023
104,906
14,301
119,207


Additions
10,500
-
10,500



At 31 July 2024

115,406
14,301
129,707



Depreciation


At 1 August 2023
91,853
13,496
105,349


Charge for the year on owned assets
3,533
201
3,734



At 31 July 2024

95,386
13,697
109,083



Net book value



At 31 July 2024
20,020
604
20,624



At 31 July 2023
13,054
805
13,859


6.


Controlling party

The company is a wholly-owned subsidiary of No. 601 Leicester Limited, a company incorporated and trading in United Kingdom. 

 
Page 8